NovoCure Limited reported operating results for the fourth Quarter and full year 2015. 555 prescriptions were received in the quarter, an increase of 108% against the prior year quarter. The company also announced that 499 of the prescriptions were received in the U.S. and 56 were received outside of the U.S., primarily in Europe.


For the year, the company announced that 1,774 prescriptions were received in the year, an increase of 151% against the prior year. The company also announced that 1,607 of the prescriptions were received in the U.S. and 167 were received outside of the U.S., primarily in Europe.